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Abstract
Background: The existence of cancer stem cells in hepatocellular carcinoma (HCC) has been verified by
characterizing side population (SP) cells based on efflux of Hoechst 33342 dye from stem cells. Recent advances in
microRNA (miRNA) biology have revealed that miRNAs play an important role in embryonic development and
tumorigenesis. However, it is still unclear which miRNAs participate in the neoplastic transformation of liver cancer
stem cells (LCSCs) during hepatocarcinogenesis.
Methods: To identify the unique set of miRNAs differentially regulated in LCSCs, we applied SP sorting to primary
cultures of F344 rat HCC cancer cells treated with diethylnitrosamine (DEN) and normal syngenic fetal liver cells,
and the stem-like characteristics of SP cells were verified through detecting expression of CD90.1, AFP and CK-7.
Global miRNA expression profiles of two groups of SP cells were screened through microarray platform.
Results: A total of 68 miRNAs, including miR-10b, miR-21, miR-470*, miR-34c-3p, and let-7i*, were identified as
overexpressed in SP of HCC cells compared to fetal liver cells. Ten miRNAs were underexpressed, including miR-
200a* and miR-148b*. These miRNAs were validated using stem-loop real-time reverse transcriptase polymerase
chain reaction (RT-PCR).
Conclusions: Our results suggest that LCSCs may have a distinct miRNA expression fingerprint during
hepatocarcinogenesis. Dissecting these relationships will provide a new understanding of the function of miRNA in
the process of neoplastic transformation of LCSCs.
Background
Cancer stem cells (CSCs) have been identified in hema-
topoietic malignancies and in solid tumors, including
hepatocellular carcinoma (HCC) [1,2]. The isolation and
characterization of CSCs are usually based on the pre-
sence of known stem cell markers, i.e., CD133 in glioma
[3] and CD44 and CD24 in breast cancer [4]. However,
for many tissues, specific molecular markers of somatic
stem cells are still unclear. Therefore, attempts have
been made to identify CSCs in solid tumors through iso-
lation of side population (SP) cells based on the efflux of
Hoechst 33342 dye; such efflux is a specific property of
stem cells [5]. The ability to isolate SP cells by cell sort-
ing makes it possible to efficiently enrich both normal
somatic stem cells and CSCs in vitro without the use of
stem cell markers.
HCC is one of the most malignant tumors in exis-
tence. By using SP sorting, the existence of liver cancer
stem cells in many established HCC cell lines has been
verified [6-8]. However, few studies have focused on the
isolation and characterization of SP cells isolated from
primitive HCC cells. We conjectured that if normal
hepatic stem cells (HSCs) and liver cancer stem cells
(LCSCs) could be enriched through SP isolation, an in
vitro model to determine whether HCC arises through
the maturational arrest of HSCs could be developed.
MicroRNAs (miRNAs) are noncoding RNAs of 19 to
25 nucleotides in length that regulate gene expression
by inducing translational inhibition and cleavage of their
target mRNAs through base-pairing to partially or fully
complementary sites [9]. Studies using the Dicer gene
knockout mouse model have demonstrated that miR-
NAs may be critical regulators of the organogenesis of
embryonic stem cells (ESC) [10,11]. Moreover, accumu-
lated data suggest that dysregulation of miRNA occurs
frequently in a variety of carcinomas, including those of
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dual effects of miRNAs in both carcinogenesis and dif-
ferentiation of normal stem cells strongly suggest that
miRNA may be involved in the transformation of nor-
mal stem cells into cancer stem cells. Therefore, screen-
ing for differences in miRNA expression between
normal HSCs and LCSCs should help to elucidate the
complex molecular mechanism of hepatocarcinogenesis.
In this study, we applied SP analysis and sorting to
F344 rat HCC cells induced with DEN and to syngenic
rat day 14 embryonic fetal liver cells. After isolation of
total RNA, microarray analysis of miRNA expression
was performed in order to detect possible differences in
expression levels of specific miRNAs in the two side
populations. We found that 68 miRNAs were over-
expressed in the side population of cancer cells com-
pared to that obtained from fetal liver cells, while 10
miRNAs were relatively under-expressed. Partially dysre-
gulated miRNAs were validated by real-time PCR analy-
sis. Our results reveal that miRNAs may play an
important function during the transformation of normal
HSCs into LCSCs.
Methods
Animals and Chemical Carcinogenesis
Pregnant F344 rats and normal male F344 rats were
purchased from the national rodent laboratory animal
resources, Shanghai branch, China. All animals were
housed in an air-conditioned room under specific patho-
gen-free (SPF) conditions at 22 ± 2°C and 55 ± 5%
humidity with a 12 hour light/dark cycle. Food and tap
water were available ad libitum. All operations were car-
ried out under approval of Fourth Military Medical Uni-
versity Animal Ethics Committee. Primary HCCs were
induced with DEN (80 mg/L in drinking water, Sigma,
St. Louis, MO) for 6 weeks; animals were then provided
with normal water until the appearance of typical tumor
nodules in the liver, which usually occurred 10 to 12
weeks after treatment. After the rats were sacrificed
under ether anesthesia, liver tissues were fixed with 4%
paraformaldehyde, routinely processed and stained with
hematoxylin and eosin (H&E) for histological examina-
tion by two pathologists, blinded to the results of the
study, in order to verify the formation of HCC.
Cell isolation and primary culture
Fetal liver cells were obtained from embryonic day 14
rat fetuses by the procedure of Nierhoff et al. [13]. The
dissociated cells were inoculated onto culture plates
with William’s E medium (Sigma, St. Louis, MO) sup-
plemented with 10% fetal calf serum (FCS) (Invitrogen),
100 U/mL penicillin G, 0.2 mg/mL streptomycin, and
500 ng/mL insulin. HCC cells were isolated from DEN-
induced rat liver carcinomas. Briefly, tumor nodules in
the liver were minced into pieces and digested by 0.5%
collagenase type IV (Sigma ,S t .L o u i s ,M O )a t3 7 ° Cf o r
15 minutes. After filtration through 70 μmm e s h ,t h e
dispersed cancer cells were collected by centrifugation
and finally cultured in medium of the same composition
as that used for fetal liver cells. The culture media were
changed routinely every 3 days.
Flow cytometry
To identify and isolate SP fractions, fetal liver cells and
HCC cells were dissociated from culture plates with
trypsin and EDTA, and pelleted by centrifugation. The
cells were resuspended at 1 × 106/mL in pre-warmed
HBSS with 2% bovine serum albumin (BSA) and
10 mmol/L HEPES. Hoechst 33342 dye was added to a
final concentration of 5 mg/mL in the presence or
absence of 50 μM verapamil (Sigma, USA), and cells
were then incubated at 37°C for 90 minutes. After incu-
bation, the cells were washed with ice-cold HBSS three
times, and were further stained with FITC-conjugated
anti-rat CD90.1 monoclonal antibody (Biolegend Co.,
USA). When staining was finished, propidium iodide
(PI; final concentration 1 μg/ml) was added to identify
viable cells. The cells were filtered through 80 μm mesh
(Becton Dickinson Co., USA) to obtain a single cell sus-
pension before analysis and sorting. Analysis and sorting
were performed on a FACSVantage II (Becton Dickin-
son Co., USA). The Hoechst 33342 dye was excited at
355 nm and its fluorescence was dual-wavelength ana-
lyzed with emission for Hoechst blue at 445 nm, and
Hoechst red at 650 nm.
RNA isolation and miRNA microarray
Total RNA from two groups of SP cells was isolated
using TRIZOL reagent (Invitrogen) according to the
instructions of the supplier and was further purified
using an RNeasy mini kit (Qiagen, Valencia, CA USA).
The miRCURY Hy3/Hy5 labeling kit (Exiqon) was used
to label purified miRNA with Hy3TM fluorescent dye.
Labeled samples were hybridized on the miRCURY LNA
(locked nucleic acid) Array (v.11.0, Exiqon, Denmark).
Each sample was run in quadruplicate. Labeling effi-
ciency was evaluated by analyzing signals from control
spike-in capture probes. LNA-modified capture probes
corresponding to human, mouse, and rat mature sense
miRNA sequences based on Sanger’sm i R B A S Ev e r s i o n
13.0 were spotted onto the slides. The hybridization was
carried out according to the manufacturer’s instructions;
a 635 nm laser was used to scan the slide using the Agi-
lent G2505B. Data were analyzed using Genepix Pro 6.0.
Statistical analysis
Signal intensities for each spot were calculated by sub-
tracting local background (based on the median intensity
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An average value of the three spot replicates of each
miRNA was generated after data transformation (to con-
vert any negative value to 0.01). Normalization was per-
formed using a per-chip 50th percentile method that
normalizes each chip on its median, allowing comparison
among chips. In two class comparisons (embryonic hepa-
tocytes SP vs. HCC SP), differentially expressed miRNAs
were identified using the adjusted t-test procedure within
the Significance Analysis of Microarrays (SAM). The SAM
Excel plug-in used here calculated a score for each gene
on the basis of the observed change in its expression rela-
tive to the standard deviation of all measurements.
Because this was a multiple test, permutations were per-
formed to calculate the false discovery rate (FDR) or q
value. miRNAs with fold-changes greater than 2 or less
than 0.5 were considered for further analysis. Hierarchical
clustering was generated for both up-regulated and down-
regulated genes and conditions using standard correlation
as a measure of similarity.
Real-time polymerase chain reaction (real-time RT-PCR)
analysis
To compare the expression of AFP and CK-7 between
SP and non-SP and validate the differential expression
of miRNAs in SP fractions, we applied real-time RT-
PCR analysis to sorted cells. Specially, stem-loop pri-
mers were used for reverse transcription reaction of
miRNAs [14]. The complementary DNA (cDNA) under-
went 40 rounds of amplification (Bio-Rad IQ5) as fol-
lows: 40 cycles of a 2-step PCR (95°C for 15 seconds,
60°C for 60 seconds) after initial denaturation (95°C for
10 minutes) with 2 μlo fc D N As o l u t i o n ,1 ×T a q M a n
SYBR Green Universal Mix PCR reaction buffer. The
sequence of primers used for amplification is listed in
Table 1. mRNA or miRNA levels were normalized using
GAPDH or U6 RNA as a internal reference gene and
compared with non-SP cells. The relative amount of
each miRNA to U6 RNA was described using the 2
-ΔΔCt
method [15].
Western blotting analysis
Cells sorted by FACS were washed twice with ice-cold
PBS and then incubated with ice-cold cell lysis
buffer (1% Nonidet P-40, 50 mmol/L HEPES, pH7.4,
150 mmol/L NaCl, 2 mmol/L ethylenediaminetetraacetic
acid, 2 mmol/L phenylmethylsulfonyl fluoride,
1 mmol/L sodium vanadate, 1 mmol/L sodium fluor-
ide, and 1× protease inhibitor mixture) to extract pro-
tein. The protein concentrations of the lysates were
measured using a Bradford protein assay kit (Bio-Rad).
All samples were separated in 12% SDS polyacrylamide
gels. Signal were revealed by primary antibodies and
IRDye700-labeled secondary antibody. The signal
intensity was determined by Odyssey Infrared Imaging
System (LI-COR Bioscience, Lincoln, NE).
Results
SP cells are present in rat HCC cancer cell
and fetal liver cells
T h ee x i s t e n c eo ft h eS Pf r a c t ion in primary fetal liver
cells and in HCC cells was confirmed by staining with
Hoechst 33342 dye to generate a Hoechst blue-red pro-
file. A small fraction of low-fluorescing cells in the
lower-left region of each profile was gated as SP. The
appearance of this fraction was blocked by verapamil, an
inhibitor of transport via multidrug resistance proteins
(Figure 1A-D). Both fetal liver cells and HCC cells
Table 1 Reverse transcription and stem-loop primers for real-time RT-PCR
Gene name Reverse transcription primer (5’-3’) PCR primers (5’-3’)
F: forward primer
R: reverse primer
miR-21 GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACTCAACA F: CGCGCTAGCTTATCAGACTGA
R: GTGCAGGGTCCGAGGT
miR-10b GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACCACAAA F: CGTCGTACCCTGTAGAACCGA
R: GTGCAGGGTCCGAGGT
miR-470* GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACTCTTCT F: GTGCGAACCAGTACCTTTCTG
R: GTGCAGGGTCCGAGGT
miR-34c-3p GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACCCTGGC F:GGTGGAATCACTAACCACACG
R: GTGCAGGGTCCGAGGT
let-7i* GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACAGCAAG F: TAGTACTGCGCAAGCTACTGC
R: GTGCAGGGTCCGAGGT
miR-200a* GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACTCCAGC F: GAGTGCATCTTACCGGACAGT
R: GTGCAGGGTCCGAGGT
miR-148b* GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACGCCTGA F: GGCGCAAGTTCTGTTATACAC
R: GTGCAGGGTCCGAGGT
U6 CGCTTCACGAATTTGCGTGTCAT F: GCTTCGGCAGCACATATACTAAAAT
R: CGCTTCACGAATTTGCGTGTCAT
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Page 3 of 10Figure 1 SP cell and non-SP cells analysis. (A and C) Representative side populations (SP) were identified in the P3 gate on the flow
cytometry profile after the cells were stained with Hoechst 33342, (B and D): The SP cells in both HCC cells and fetal liver cells disappeared
(0.0%) when cells are treated with 50 μM verapamil. (E-H) Analysis of stem cell marker expression on the surfaces of SP and non-SP cells. The
number within each histogram represents the percentage of CD90.1 positive cells. (I-K) Quantitative analysis of AFP and CK-7 genes expression
applied to sorted SP cells and non-SP cells by using Real-time RT-PCR. Data were normalized by using GAPDH housekeeping gene as
endogenous control. (* P < 0.05, ** P < 0.01). (L-M) Western-blotting analysis of AFP and CK-7 protein expression in SP cells and non-SP cells.
The relative expressions of protein were calculated through comparing with GAPDH protein.
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liver cells was calculated to be 0.15% ± 0.02% (mean ±
SEM), and that of HCC cells was calculated to be 0.20%
± 0.08%. Once identified, the cells in the SP gate were
sorted into a centrifuge pipe by FACS.
SP cells are enriched for markers of HSCs
To examine whether SP cells are enriched for character-
istics of stem cells compared to the non-SP cells, we
further characterized the SP cells from the fetal liver
cells and HCC cells by analyzing the presence of mar-
kers known to be expressed commonly on the surface of
HSCs. FACS analysis showed that CD90.1 positive cells
made up 45% ± 2.7% of total SP from fetal liver cells,
and 37% ± 2.1% of total SP from HCC cells. In contrast,
only 0.1% ± 0.0% (fetal liver cells) and 0.8% ± 0.1%
(HCC cells) were CD90.1 positive cells in non-SP frac-
tions (Figure 1E-H). We next quantitatively compared
the expression of AFP and CK-7 genes between sorted
SP cells and non-SP cells. Real-time RT-PCR analysis
revealed that AFP and CK-7 mRNA level in SP from the
fetal liver cells were increased 4.3-fold and 1.9-fold,
respectively compared to non-SP (Figure 1I). Similarly,
in SP from the HCC cells, they were increased 3.6-fold
and 2.7-fold, respectively (Figure 1J). Furthermore, the
differentially gene expressing profile of AFP and CK-7
in sorted SP cells and non-SP cells also confirmed by
using western-blotting analysis. As shown in Figure, the
relative expression of AFP and CK-7 were 0.84 ± 0.10,
0.53 ± 0.01 in SP from the fetal liver cells. While they
were only 0.20 ± 0.08 and 0.18 ± 0.05 in non-SP cells
(Figure 1L). Similar results also could be seen in HCC
cells group (SP: 1.17 ± 0.0.14, 0.47 ± 0.10; non-SP: 0.35
± 0.12, 0.16 ± 0.04) (Figure 1M). These results indicate
that the SP fraction appeared to be enriched with HSCs
or LCSCs.
miRNAs are differentially expressed in
SP of fetal liver cells and HCC cells
To identify specific miRNAs that might function in neo-
plastic transformation of liver cancer stem cells, we ana-
lyzed global miRNA expression using miRCURY LNA
Array that covered all microRNAs in miRBase. Slides
were scanned using an Agilent G2565BA Microarray
Scanner System and image analysis was carried out with
ImaGene 7.0 software (BioDiscovery). The array data
was further analyzed using SAM. Based on the fold-
changes observed, 68 up-regulated miRNAs and 10
down-regulated miRNAs were identified in the SP of
HCC cells compared to the fetal liver cells. A compre-
hensive list is shown in Table 2. The SAM analysis plot
image is shown in Figure 2, and a hierarchical clustering
image is shown in Figure 3.
Validation of the differentially expressed
miRNAs by qRT-PCR
Using a stringent cut-off of P < 0.05, we found signifi-
cantly altered expression of only 7 of all rat miRNAs
analyzed in SP of HCC cells. In detail, five miRNAs
were significantly up-regulated (miR-21, miR-34c-3p,
miR-470*, miR-10b, let-7i*) and two miRNAs signifi-
cantly down-regulated in SP of HCC cells (miR-200a*,
miR-148b*). miRNA-specific qRT-PCR was used to vali-
date the significantly altered miRNAs from the miRNA
microarray results. As shown in Figure 4A, the results
showed that the expression levels of miR-21, miR-34c-
3p, miR-16, miR-10b, and let-7i* in SP of HCC cells
compared to SP of fetal liver cells were increased 3.5 ±
0.84, 2.1 ± 0.52, 2.2 ± 0.46, 3.9 ± 0.61, and 2.8 ± 0.25
-fold respectively, which were consistent with miRNA
microarray results (P < 0.05). of the down-regulated
miR-200a*, and miR-148b* in SP of HCC cells had the
Table 2 Partial list of miRNAs with significantly different
levels detected in SP of HCC cells compared to fetal liver
cells
microRNA SAM
score
Fold
change
False discovery rate
(FDR) %
hsa-miR-935 0.66 4.32 0.51
mmu-miR-10b 1.00 3.88 0.07
mmu-miR-21 0.80 2.96 0.00
mmu-miR-470* 0.69 2.81 0.00
hsa-miR-34c-3p 0.78 2.79 0.00
hsa-miR-650 0.76 2.71 0.00
hsa-miR-92b* 0.69 2.65 0.03
hsa-miR-193b 0.71 2.59 0.00
hsa-miR-374a* 0.68 2.58 0.24
hsa-miR-548c-3p 0.70 2.54 0.00
hsa-miR-33b 0.66 2.53 0.57
mmu-miR-199a-3p 0.71 2.52 0.00
hsa-miR-330-3p 0.71 2.51 0.00
mmu-miR-376a 0.69 2.48 0.13
mmu-miR-100 0.68 2.44 0.16
mmu-miR-717 0.66 2.36 0.62
mmu-miR-125b-5p 0.66 2.35 0.45
mmu-miR-449a 0.64 2.35 1.09
hsa-miR-21* 0.63 2.31 1.29
mmu-miR-883b-3p 0.63 2.29 1.20
mmu-miR-31 0.59 2.25 2.45
mmu-miR-34b-3p 0.57 2.14 3.43
mmu-let-7i* 0.55 2.02 4.66
hsa-miR-549 -0.70 0.05 2.84
mmu-miR-207 -0.86 0.23 6.02
mmu-miR-200a* -0.94 0.29 1.22
mmu-miR-207 -0.86 0.23 0.60
hsa-miR-148b* -0.76 0.36 2.72
mmu-miR-135a* -0.69 0.38 2.92
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0.01).
To further confirm the differentially expressed
miRNA, some known target genes expression of those
validated miRNAs excluded miR-470* and miR-148b
were detected in sorted SP cells and compared by using
qRT-PCR between fetal liver cell and HCC cells. These
target genes were PTEN (miR-21), P53 (miR-34c), Rho
C (miR-10b), RAS (let-7i), and ZEB1 (miR-200a). As
s h o w ni nF i g u r e4 B ,t h er e l a t i v eg e n ee x p r e s s i o no f
PTEN, P53, RhoC and RAS in SP from HCC cells were
significantly lower than in fetal liver cells. On the con-
trary, the relative expression of ZEB1 gene in SP from
HCC cells was higher than in fetal liver cells. Respec-
tively, corresponding specific data were 0.78 ± 0.24 vs
0.33 ± 0.18 (PTEN), 1.79 ± 0.36 vs 0.81 ± 0.29 (P53),
1.16 ± 0.44 vs 0.72 ± 0.34 (RhoC), 3.52 ± 1.13 vs 1.62 ±
0.92 (RAS), and 0.27 ± 0.11 vs 0.48 ± 0.13 (ZEB1).
These data were indirectly validated the differentially
expressing profile of those miRNAs in SP fractions
between HCC cells and fetal liver cells.
Discussion
There is a growing realization that many cancers may
harbor a small population of cancer stem cells (CSCs).
These cells not only exhibit stem cell characteristics, but
also, importantly, are tumor-initiating cells and are
responsible for cellular heterogeneity of cancer due to
aberrant differentiation. According to the hierarchical
model of cancer, the origin of the cancer stem cells may
be long-lived somatic stem cells. Therefore, markers of
“normal” stem cells are being sought with the expecta-
tion that these molecules are also expressed by cancer
stem cells, and can be used to identify them. In fact, the
specific markers of many somatic stem cells, e.g., HSCs,
are still unidentified, and it is difficult to screen putative
stem cell markers useful for isolation and characteriza-
tion of liver cancer stem cells. Recently, however, a spe-
cial common “marker” has been identified in the sense
that characteristic stem-like cells possess an energy-
dependent drug export property conferred by their high
expression of ABC (ATP-binding cassette) membrane
transporters. This property was first exploited by Good-
ell et al. [16] for isolation and analysis of hematopoietic
stem cells based on their ability to efflux a fluorescent
dye. Identified cells were termed a “side population”.
The SP fraction is a useful tool for cancer stem cell stu-
dies in solid tumors, especially when specific cell surface
markers are unknown. In many gastrointestinal cancers
and HCC cell lines, SP fraction cells have been identi-
fied and characterized by their capacity for self-renewal
and their high tumorgenicity [17]. These studies demon-
strated that SP can be used to enrich cancer stem cells
in HCC. Moreover, it has been verified that normal
HSCs (or ‘oval cells’) in rodents also express the side
population phenotype defined by high expression of
ABC transporter [18,19]. In the current study, we were
able to identify a small SP component (0.10%-0.34%) in
both fetal liver cells and HCC cancer cells of F344 rats.
The percentage of SP cells we detected is similar to the
percentages described in most previous reports of SP in
human HCC cell lines[17]. To the best of our knowl-
edge, this is the first report demonstrating the existence
of SP cells in both fetal liver cells and in primary rodent
HCC cancer cells induced by chemical carcinogens.
Since the HCC cancer cells and fetal liver cells used in
our study originated from the same inbred rat strain,
the SP fractions enriched by screening both normal fetal
liver and tumors for stem-like cell characteristics have
high similarity in genetic background, thus providing a
model for in vitro study of the mechanism of neoplastic
transformation from normal HSCs into LCSCs. In con-
trast, it is difficult to accomplish this using SP cells
sorted from many human HCC cell lines.
Increasing evidence has accumulated suggesting that
many miRNAs play key roles in stem cell maintenance
and differentiation. In ESC, disruption of the Dicer pro-
tein, an important enzyme in miRNA processing, leads
to embryonic lethality [20]. Further evidence has also
been provided by studies in some somatic stem cells
showing that specific miRNA-based regulation is
involved during organ and tissue development; e.g., a
cardiac-enriched miRNA family was identified and
demonstrated to have a critical role in the differentiation
and proliferation of cardiac progenitor cells [21]. Addi-
tionally, experiments using isolated populations of
hematopoietic stem cells have documented roles for
Figure 2 SAM outputs. SAM plotsheet outputs under the four sets
of criteria: Δ = 0.25, fold change = 2. Conditions are indicated at
the upper right corner of each plotsheet. The red, green, and black
dots represent upregulated, downregulated, and insignificantly
changed miRNAs, respectively. The upper and lower 45° degree
lines indicate the Δ threshold boundaries. The number of significant
miRNAs, median number of false positives, and false discovery rate
(FDR) are indicated at the upper left corner of the plotsheet.
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Page 6 of 10Figure 3 Heat map of altered miRNA expression. A heat map was generated using the expression ratios of 78 miRNAs that differed
significantly in SP of HCC cells compared to fetal liver cells, according to significance analysis of microarrays (SAM). Red, overexpressed miRNAs;
green, underexpressed miRNAs compared to counterparts. Relatedness in miRNA expression across samples is shown by a hierarchical tree on
the Y axis through standard linkage.
Li et al. Journal of Experimental & Clinical Cancer Research 2010, 29:169
http://www.jeccr.com/content/29/1/169
Page 7 of 10specific miRNAs in HSC lineage differentiation, and evi-
dence suggests that miRNAs are important for differen-
tiation of somatic stem cells in several other tissues as
well [22]. In addition to stem cell studies, microarray-
based expression studies have also shown that aberrant
expression of miRNAs occurs in several hematological
and solid tumors including HCC [12]. In these malig-
nancies, it has been shown that specific miRNAs can
function either as oncogenes or as tumor suppressors
during carcinogenesis [23]. Moreover, the aberrant
miRNA expression profile correlated with particular
tumor phenotypes can even be used to distinguish
between normal tissue and tumors.
With the accumulation of evidence for “cancer stem
cells”,i ti sp r o p o s e dt h a tm i R N A sm i g h tp l a yar o l ei n
malignant transformation from normal stem cells into
cancer stem cells. Recent studies have partially verified
this hypothesis; e.g., let-7 miRNA expression can be
observed in ESC and progenitor cells, but is absent in
breast cancer stem cells. The reintroduction of let-7 into
these cells causes differentiation and reduction of prolif-
eration and tumor-forming ability. It has been demon-
strated that in carcinogenesis, some miRNAs are likely
to be instrumental in helping to control the delicate bal-
ance between the extraordinary ability of stem cells to
self-renew, and their ability to differentiate for the pur-
pose of development and tissue maintenance versus
their potential for dysregulated growth and tumor for-
mation [24]. In the present work, we have identified, for
the first time, miRNA expression patterns that can
unambiguously differentiate LCSCs and normal HSCs,
though both were enriched in SP fractions and showed
similar phenotypes. Our study demonstrates that the
aberrant expression of some specific miRNAs may play
a key regulatory role in the hepatocarcinogenesis of
HSCs. Notably, the dysregulated miRNAs identified in
our study are encoded in chromosomal regions that
have frequent chromosomal instability during hepatocar-
cinogenesis, verified by previous comparative genomic
hybridization. For example, the precursor sequences of
the up-regulated miRNAs (miR-21, miR-10b) and down-
regulated miR-148b* observed in our study are located
at 17q23, 3q23 and 12q13. In these regions, chromoso-
mal aberrations such as recurrent amplification, methy-
lation or loss of heterozygosity have been detected in
various clinicopathological HCC samples [25,26]. It has
been shown that miRNA expression profiles of cancer
stem cells are tissue-specific and tumor-specific. More-
over, comprehensive analysis of miRNA expression in
diverse tumors has shown that miRNA genetic finger-
p r i n t sc a nb eu s e dt oa c c u r a t e l yd i a g n o s ea n dp r e d i c t
tumor behavior [27,28]. While liver cancer stem cells
are believed to be the tumor-initiating cells of HCC, we
speculate that screening of circulating miRNAs in the
serum could help to predict the presence of liver cancer
stem cells and that such a procedure may be useful for
early diagnosis of HCC.
Here we validated significant overexpression of miR-
10b, miR-21, and miR-34c-3p in SP fractions of HCC
compared to SP fractions of normal fetal liver cells.
Notably, overexpression of these three miRNAs was pre-
viously shown to be an important factor in promoting
cell invasion or proliferation in various tumor types. By
performing real-time PCR, Sasayama et al. [29] found
Figure 4 Validation of microarray data using real-time RT-PCR. (A) The levels of miR-21, miR-34c-3p, miR-470*, miR-10b and let-7i* are
significantly increased, while the levels of miR-200a*, miR-148b are significantly decreased in the SP of HCC cells compared to the fetal liver
cells, according to the results of microarray analysis (gray bar). Real-time RT-PCR analysis of these miRNAs using total RNA isolated from the SP
fractions showed similar results (white bar). (B) Real-time analysis revealed that some known target genes of those partially validated miRNAs are
also significantly differentially expressed between the SP sorted from the HCC cells and fetal liver cells (* P < 0.05; ** P < 0.01). The levels of
target gene mRNA are inversely correlated with associated microRNA expression in SP cells.
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that the expression of miR-10b was associated with
higher-grade glioma. In glioma cells, miR-10b regulates
the expression of mRNA for RhoC and urokinase-type
plasminogen activator receptor (uPAR) via inhibition of
translation of the mRNA encoding homeobox D 10
(HOXD 10), resulting in invasion and metastasis of
glioma cells. Similarly, overexpression of miR-10b was
also detected in metastatic breast cancer by Ma et al.
[30], who showed that increased expression of miR-10b
promoted cell migration and invasion. Additionally, it
has been verified that miR-21 overexpression can down-
regulate the Pdcd4 tumor suppressor and stimulate
invasion, intravasation and metastasis in colorectal can-
cer [31]. Moreover, overexpression of miR-21 was also
previously associated with poorly differentiated HCC,
and this miRNA is known to participate in down-regula-
tion of phosphatase and tensin homolog (PTEN) [32]. A
different situation exists with other miRNAs such as
miR-34c-3p, which is a member of the miR-34 family.
Members of this family have been shown to be targets
of the p53 gene, and to be involved in control of cell
proliferation [33]. However, since inactivation of p53 is
a critical event during hepatocarcinogenesis, it has been
suggested that miRNAs play a central role in the aber-
rance of the p53 tumor suppressor network during neo-
plastic transformation of liver cancer stem cells, and
that this is linked with multiple changes of phenotype
such as cell cycle arrest and apoptosis.
A subset of miRNAs was also identified and shown to
be significantly underexpressed in our study, including
miR-200a and miR-148b*. Previous studies have linked
the miR-200 family with the epithelial phenotype [34],
and Korpal et al. [35] identified miR-200a as a suppres-
sor of epithelial-mesenchymal transition (EMT) through
direct targeting of ZEB1 and ZEB2 genes. EMT is a cru-
cial process in the formation of various tissues and
organs during embryonic development. Moreover, EMT
is proposed to be a key step in the metastasis of epithe-
lial-derived tumors including HCC. Thus, we hypothe-
size that the down-regulated miRNAs seen in this study
may function as tumor suppressor genes during carcino-
genesis. Although the exact target mRNA targets for
many miRNAs are currently unknown, use of the Tar-
getScan and MiRanda database to identify predicted tar-
get genes of the miRNAs shown to be up-regulated or
down-regulated in our study could help to elucidate the
neoplastic mechanism of liver cancer stem cells.
Conclusions
This work provides an in vivo model for the study of
mechanisms of neoplastic transformation of liver cancer
stem cells by separately sorting SP fractions enriched
with stem-like cells from primary rat HCC cancer cells
and syngenic fetal liver cells. On the basis of this model,
differences in miRNA expression profiles between
LCSCs and normal HSCs were investigated using micro-
arrays. This allowed us to identify miRNAs whose
deregulation was closely correlated with the malignant
phenotype of liver cancer stem cells, as distinguished
from normal hepatic stem cells and from oncogene and
tumor suppressor gene mutations. The gene and protein
networks directly targeted and affected by these miR-
NAs that are likely to participate in tumorigenesis
remain to be explored.
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